Therapeutic Advances in Functional Gastrointestinal Disease: Irritable Bowel Syndrome

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2009 Nov 26

PMID 19936327

Citations 5

Authors

Alexandru Gaman

Maria Cristina Bucur

Braden Kuo

Affiliations

Soon will be listed here.

Abstract

Reported prevalence rates of irritable bowel syndrome (IBS) are between 8% to 20% in the US general population with an average medical expenditure of US$1.35 billion direct and US$205 million indirect costs. Current pathophysiologic theories are based on abnormalities of both the brain and gut, thus setting a new stage for current and future therapeutic approaches. There are numerous treatment options in IBS acting centrally and peripherally by influencing motility and visceral sensitivity. Clinical evidence is variable; however, newer emerging treatments are being evaluated using better-designed clinical trials. Accurate assessment of IBS drug efficacy is still hampered by heterogeneity of the IBS population. Novel methods such as pharmacogenomics or brain imaging may be helpful in the future to better understand and characterize IBS patient subtypes, and this in turn will lead to more specific and efficient therapeutic options. Patient subpopulation measurement of side effects is also a clinical challenge and further understanding could improve treatment efficacy enhancing the patient compliance.

Citing Articles

Comparison between gluten-free regime and regime with gluten in symptoms of patients with irritable bowel syndrome (IBS).

Hajiani E, Masjedizadeh A, Shayesteh A, Babazadeh S, Seyedian S J Family Med Prim Care. 2019; 8(5):1691-1695.

PMID: 31198738 PMC: 6559066. DOI: 10.4103/jfmpc.jfmpc_464_18.

Efficacy of individualised diets in patients with irritable bowel syndrome: a randomised controlled trial.

Ali A, Weiss T, McKee D, Scherban A, Khan S, Fields M BMJ Open Gastroenterol. 2017; 4(1):e000164.

PMID: 29018540 PMC: 5628288. DOI: 10.1136/bmjgast-2017-000164.

Cumin extract for symptom control in patients with irritable bowel syndrome: a case series.

Agah S, Taleb A, Moeini R, Gorji N, Nikbakht H Middle East J Dig Dis. 2014; 5(4):217-22.

PMID: 24829694 PMC: 3990147.

Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome.

Magge S, Lembo A Gastroenterol Hepatol (N Y). 2014; 8(11):739-45.

PMID: 24672410 PMC: 3966170.

Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial.

Gaylord S, Palsson O, Garland E, Faurot K, Coble R, Mann J Am J Gastroenterol. 2011; 106(9):1678-88.

PMID: 21691341 PMC: 6502251. DOI: 10.1038/ajg.2011.184.

References

Sanger G, Wardle K . Constipation evoked by 5-HT3-receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. J Pharm Pharmacol. 1994; 46(8):666-70. DOI: 10.1111/j.2042-7158.1994.tb03879.x. View

Julia V, Morteau O, Bueno L . Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology. 1994; 107(1):94-102. DOI: 10.1016/0016-5085(94)90065-5. View

Tayama J, Sagami Y, Shimada Y, Hongo M, Fukudo S . Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2007; 19(6):471-83. DOI: 10.1111/j.1365-2982.2007.00903.x. View

Harasiuk A, Klupinska G, Walecka-Kapica E, Forys S, Felicka E, Piotrowski W . [Secretion of serotonin and melatonin in patients with functional dyspepsia]. Pol Merkur Lekarski. 2007; 22(131):336-40. View

Eutamene H, Theodorou V, Fioramonti J, Bueno L . Rectal distention-induced colonic net water secretion in rats involves tachykinins, capsaicin sensory, and vagus nerves. Gastroenterology. 1997; 112(5):1595-602. DOI: 10.1016/s0016-5085(97)70041-6. View

Tache Y, Martinez V, Wang L, Million M . CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol. 2004; 141(8):1321-30. PMC: 1574904. DOI: 10.1038/sj.bjp.0705760. View

Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N . The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003; 124(2):303-17. DOI: 10.1053/gast.2003.50055. View

Hasler W, Soudah H, Owyang C . A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology. 1993; 104(5):1390-7. DOI: 10.1016/0016-5085(93)90347-f. View

Awouters F, Megens A, Verlinden M, Schuurkes J, NIEMEGEERS C, Janssen P . Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci. 1993; 38(6):977-95. DOI: 10.1007/BF01295711. View

10.

Miranda A, Peles S, McLean P, Sengupta J . Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia. Pain. 2006; 126(1-3):54-63. DOI: 10.1016/j.pain.2006.06.014. View

11.

Okano S, Nagaya H, Ikeura Y, Natsugari H, Inatomi N . Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J Pharmacol Exp Ther. 2001; 298(2):559-64. View

12.

Viscusi E, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K . Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2005; 20(1):64-70. DOI: 10.1007/s00464-005-0104-y. View

13.

Banks W, Schally A, Barrera C, Fasold M, Durham D, Csernus V . Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1990; 87(17):6762-6. PMC: 54617. DOI: 10.1073/pnas.87.17.6762. View

14.

Emmanuel A, Roy A, Nicholls T, Kamm M . Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002; 16(7):1347-56. DOI: 10.1046/j.1365-2036.2002.01272.x. View

15.

Emery P, Higgs N, Warhurst A, Carlson G, Warhurst G . Anti-secretory properties of non-peptide somatostatin receptor agonists in isolated rat colon: luminal activity and possible interaction with P-glycoprotein. Br J Pharmacol. 2002; 135(6):1443-8. PMC: 1573276. DOI: 10.1038/sj.bjp.0704614. View

16.

Roka R, Rosztoczy A, Leveque M, Izbeki F, Nagy F, Molnar T . A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007; 5(5):550-5. DOI: 10.1016/j.cgh.2006.12.004. View

17.

Lembo T, Wright R, Bagby B, Decker C, Gordon S, Jhingran P . Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001; 96(9):2662-70. DOI: 10.1111/j.1572-0241.2001.04128.x. View

18.

Evans B, Clark W, Moore D, Whorwell P . Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2004; (1):CD003960. DOI: 10.1002/14651858.CD003960.pub2. View

19.

George A, Meyers N, Hickling R . Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther. 2008; 27(9):830-7. DOI: 10.1111/j.1365-2036.2008.03649.x. View

20.

Wang H, Zhang Y, Ding Y, Zhang J . Localization of neurokinin B receptor in mouse gastrointestinal tract. World J Gastroenterol. 2002; 8(1):172-5. PMC: 4656613. DOI: 10.3748/wjg.v8.i1.172. View